Peter Garrambone, Jr.
Principal
peter.garrambone@torreyapartners.com
(917) 742-5017
Pete concentrates his practice on M&A transactions, often leading negotiations and quantitative analysis underpinning a transaction. He has 25 years of pharmaceutical industry experience and has been involved in over $200 billion worth of M&A transactions. Pete has strong and diverse experience with past roles in operations, strategic planning and financial management in both medical devices and pharmaceuticals. He was most recently Senior Vice President, Business Development at Reliant Pharmaceuticals. At Reliant Pete helped in the sale to GlaxoSmithKline for $1.65 billion. Previously, he spent 24 years at Pfizer, where he held a number of business development, financial and strategic planning positions in its corporate, human pharmaceutical and medical device organizations. Most recently, Pete was Senior Vice President, Corporate Strategic Planning where he oversaw numerous biotech company and product rights acquisitions as well as business divestitures. Key transaction accomplishments include Pfizer’s acquisitions of Warner-Lambert and Pharmacia as well as the divestiture of Pfizer’s consumer products business to Johnson and Johnson. Pete currently is interim-CEO and serves on the Board of Directors of Aegerion Pharmaceuticals. Pete is a graduate of Colby College and holds an M.B.A. from Dartmouth.
Selected Transaction Experience:
• Teikoku Pharma USA, Acquisition of Travanti Pharma (2009)
• Navitas Pharma, Sale to Gilead (2008)
• Reliant Pharmaceuticals, Sale to GlaxoSmithKline, $1.65 billion (2007)
• Pfizer, Sale of Pfizer Consumer Healthcare to Johnson & Johnson, $16.6 billion (2006)
• Pfizer, Acquisition of PowderMed (2006)
• Pfizer, Acquisition of Rinat (2006)
• Pfizer, Purchase of Exubera from Sanofi-Aventis, $1.3 billion (2006)
• Pfizer, Acquisition of Vicuron, $1.9 billion (2005)
• Pfizer, Acquisition of Idun (2005)
• Pfizer, Acquisition of Meridica, $125 million (2004)
• Pfizer, Divestiture of Surgical Ophthalmology Business to American Medical Optics, $450 million (2004)
• Pfizer, Divestiture of Nerviano Research Center to CFIC (2004)
• Pfizer, Divestiture of Pharmacia Diagnostics to Triton Advisers and PPM Capital, $575 million (2004)
• Pfizer, Acquisition of Esperion, $1.3 billion (2004)
• Pfizer, Divestiture of Schick to Energizer, $930 million (2003)
• Pfizer, Divestiture of Adams to Cadbury Schweppes, $4.2 billion (2002)
• Pfizer, Divestiture of Tetra to Triton, $239 million (2002)
• Pfizer, Acquisition of Pharmacia, $56 billion (2003)
• Pfizer, Acquisition of Warner Lambert, $117 billion (2000)
• Pfizer, Divestiture of American Medical Systems to Warburg Pincus, $125 million (1998)
• Pfizer, Divestiture of Howmedica to Stryker, $1.65 billion (1998)
• Pfizer, Divestiture of Schneider to Boston Scientific, $2.1 billion, (1998)
• Pfizer, Divestiture of Valleylab to U.S. Surgical Corporation, $425 million (1997)
• Pfizer, Disease Management Alliance with a PBM (1996)
• Pfizer, Acquisition of NAMIC USA, $170 million (1995)
• Pfizer, Divestiture of Shiley to SNIA, $250 million (1992)
• Pfizer, Divestiture of Deknatel to Deknatel Management and Outside Investors, $110 million (1991)
• Pfizer, Acquisition of Medinvent, $100 million (1987)
• Pfizer, Acquisition of Angiomedics, $70 million (1986)
• Pfizer, Acquisition of American Medical Systems, $100 million (1985)
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.